WASHINGTON (AFP) – The success of an Aids vaccine trial that in 2009 was shown to protect 31 per cent of people studied may have been due to varying levels of antibody responses in the patients, researchers said on Thursday.
Different types of antibody responses were associated with who became infected and who did not, according to an analysis of the results published in the April 5 edition of the New England Journal of Medicine.
For instance, a type of antibody produced by the body to ward off infection, known as IgG, could attach itself to the surface of the HIV protein and appeared to help prevent infection in some people.
People received the vaccine and whose IgG antibodies were able to bind to this region, called V1V2, showed lower infection rates than the placebo group.
There is over thirty seven potent immune factors found in properly processed Bovine Colostrum, the cure for Aids can be found in one of them. When you find the right properties, you need to increase the dose substantially to combat the Aid’s virus. – Contributed by Oogle.